Paper Details

  1. Home
  2. Paper Details

Long-term safety and efficacy of bimatoprost solution 0·03% application to the eyelid margin for the treatment of idiopathic and chemotherapy-induced eyelash hypotrichosis: a randomized controlled trial.

Author: AhluwaliaG, BeddingfieldF C, GlaserD A, GriffithsT, HossainP, PerkinsW, WengE

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

This multicenter, double-masked, randomized study of 127 patients with idiopathic or chemotherapy-induced hypotrichosis found that daily treatment with bimatoprost ophthalmic solution 0.03% for 1 year was effective and well tolerated. Treatment effects were maintained for approximately 2 months after treatment cessation in patients with idiopathic hypotrichosis.
Paper Details　
Original Abstract of the Article :
BACKGROUND: Bimatoprost ophthalmic solution 0·03% is approved in several countries for the treatment of eyelash hypotrichosis. Previous trials were limited to 4 months of treatment and primarily idiopathic hypotrichosis. OBJECTIVES: To evaluate the long-term safety and efficacy of bimatoprost in pa...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4832276/

データ提供：米国国立医学図書館（NLM）

Bimatoprost: A Promising Treatment for Eyelash Hypotrichosis

The vast desert of ophthalmology is a continuous search for effective treatments for eye-related conditions. This study investigates the long-term safety and efficacy of bimatoprost, a medication used to treat eyelash hypotrichosis, a condition characterized by thin or sparse eyelashes. The researchers conducted a double-masked, randomized controlled trial, evaluating the effects of bimatoprost over a period of 12 months in patients with both idiopathic and chemotherapy-induced eyelash hypotrichosis.

Bimatoprost: A Potential Oasis for Eyelash Growth

The study found that bimatoprost was effective in promoting eyelash growth in both idiopathic and chemotherapy-induced hypotrichosis. The researchers observed significant improvements in eyelash length, density, and overall appearance in patients treated with bimatoprost. Imagine a camel traversing a desert landscape, seeking a lush oasis of vegetation. Bimatoprost in this analogy represents the oasis, providing the necessary nutrients and conditions for eyelash growth to flourish.

A New Hope for Fuller and Thicker Eyelashes

This research offers a promising treatment option for individuals seeking to improve the appearance and fullness of their eyelashes. The study's findings suggest that bimatoprost can be an effective and safe option for both idiopathic and chemotherapy-induced eyelash hypotrichosis.

Dr. Camel's Conclusion

The journey to restore eyelash fullness and confidence is often a challenging one. This study offers hope for those seeking to improve their eyelashes, highlighting the potential of bimatoprost as a safe and effective treatment option. As we continue to explore the vast desert of ophthalmology, we are constantly seeking new oases of knowledge to improve the lives of those facing eye-related challenges.

Date :
  1. Date Completed 2016-02-01
  2. Date Revised 2021-10-21
Further Info :

Pubmed ID

25296533

DOI: Digital Object Identifier

PMC4832276

Related Literature

Article Analysis
・Effects of bimatoprost ophthalmic
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.